Home » LIGHT SCIENCES ONCOLOGY COMPLETES SECOND CLOSING IN $67 MILLION FINANCING FOR LATE STAGE DEVELOPMENT OF LITX
LIGHT SCIENCES ONCOLOGY COMPLETES SECOND CLOSING IN $67 MILLION FINANCING FOR LATE STAGE DEVELOPMENT OF LITX
Light Sciences Oncology, Inc., a privately held company focused on the development
of Light Infusion Technology (Litx) for the treatment of solid tumors, announced
today that it has completed an offering of an additional $32 million of its
Series A Preferred Stock. The completion follows by two months the initial closing
of $35 million of Series A Preferred and brings the total amount of Series A
Preferred to $67 million.
Business
Wire
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May